CD274 and non-small cell lung carcinoma: According to a study of two institutions that examined the clinical and drug dispensing records of 640 patients with advanced non-small cell lung cancer treated with a programmed death-ligand 1 (PD-(L)1) inhibitor alone, those who received a prednisolone (PSL) equivalent dose of ≥ 10 mg/day (90 patients, 14.1%) at the start of PD-(L)1 inhibitor treatment had a poor overall response rate, PFS, and OS.